Compare Dr. Reddys with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs FULFORD INDIA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB FULFORD INDIA DR. REDDYS LAB/
FULFORD INDIA
 
P/E (TTM) x 37.2 398.8 9.3% View Chart
P/BV x 4.3 6.2 70.0% View Chart
Dividend Yield % 0.5 0.1 641.7%  

Financials

 DR. REDDYS LAB   FULFORD INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
FULFORD INDIA
Mar-14
DR. REDDYS LAB/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs2,875942 305.2%   
Low Rs1,888450 419.6%   
Sales per share (Unadj.) Rs930.2691.4 134.5%  
Earnings per share (Unadj.) Rs117.411.5 1,024.5%  
Cash flow per share (Unadj.) Rs185.815.4 1,209.4%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.80.3 292.3%  
Book value per share (Unadj.) Rs844.4380.0 222.2%  
Shares outstanding (eoy) m166.073.90 4,258.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.0 254.3%   
Avg P/E ratio x20.360.7 33.4%  
P/CF ratio (eoy) x12.845.3 28.3%  
Price / Book Value ratio x2.81.8 154.0%  
Dividend payout %17.017.4 97.6%   
Avg Mkt Cap Rs m395,4962,714 14,570.3%   
No. of employees `00022.00.4 4,947.3%   
Total wages/salary Rs m33,562505 6,645.9%   
Avg. sales/employee Rs Th7,032.86,073.0 115.8%   
Avg. wages/employee Rs Th1,527.91,137.4 134.3%   
Avg. net profit/employee Rs Th887.7100.7 881.8%   
INCOME DATA
Net Sales Rs m154,4822,696 5,729.2%  
Other income Rs m3,375125 2,691.4%   
Total revenues Rs m157,8572,822 5,594.2%   
Gross profit Rs m31,782-46 -68,495.7%  
Depreciation Rs m11,34815 74,657.9%   
Interest Rs m88910 9,357.9%   
Profit before tax Rs m22,92054 42,209.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,85810 40,187.5%   
Profit after tax Rs m19,50045 43,624.2%  
Gross profit margin %20.6-1.7 -1,195.6%  
Effective tax rate %16.817.7 95.2%   
Net profit margin %12.61.7 761.4%  
BALANCE SHEET DATA
Current assets Rs m111,1011,738 6,391.4%   
Current liabilities Rs m58,973545 10,826.7%   
Net working cap to sales %33.744.3 76.2%  
Current ratio x1.93.2 59.0%  
Inventory Days Days7948 163.7%  
Debtors Days Days944 2,188.3%  
Net fixed assets Rs m101,24512 850,798.3%   
Share capital Rs m83039 2,128.2%   
"Free" reserves Rs m139,4061,443 9,660.8%   
Net worth Rs m140,2361,482 9,462.6%   
Long term debt Rs m22,0000-   
Total assets Rs m224,6562,077 10,817.9%  
Interest coverage x26.86.7 398.8%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.71.3 53.0%   
Return on assets %9.12.6 347.7%  
Return on equity %13.93.0 461.0%  
Return on capital %14.94.3 347.2%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m88,67317 515,540.7%   
Fx outflow Rs m19,104673 2,838.0%   
Net fx Rs m69,569-656 -10,605.7%   
CASH FLOW
From Operations Rs m28,70490 31,893.3%  
From Investments Rs m-7,727105 -7,387.2%  
From Financial Activity Rs m-21,326-14 151,248.2%  
Net Cashflow Rs m-314181 -174.0%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 3.8 142.1%  
FIIs % 35.3 0.1 35,300.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 21.2 72.2%  
Shareholders   75,885 4,783 1,586.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 173 Points Lower; IT and Realty Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure during closing hours today, tracking weakness in global markets owing to coronavirus outbreak.

Related Views on News

TORRENT PHARMA at 52 Week High; BSE 500 Index Down 0.5 % (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

TORRENT PHARMA share price has hit a 52-week high. It is presently trading at Rs 2,509. BSE 500 Index is down by 0.5% at 11,314. Within the BSE 500, TORRENT PHARMA (up 3.3%) and IPCA LABS (up 18.8%) are among the top gainers, while top losers are MINDA CORPORATION and ORIENT CEMENT.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 8, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS